Dr. Hacker has disclosed that her spouse has stock in Celgene Corporation, AbbVie Inc., Gilead Sciences, Inc., and Halozyme Therapeutics; her spouse receives salary from Strata Oncology. The remaining authors have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Miranda Hughes, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
Serov SF, Scully RE, Sobin LH. Histological Typing of Ovarian Tumors. International Histologic Classification of Tumours, No. 9. Geneva, Switzerland: World Health Organization; 1973.
Morris CR, Liu L, Rodriguez AO et al.. Epidemiologic features of borderline ovarian tumors in California: a population-based study. Cancer Causes Control 2013;24:665–674.
Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008;123:1897–1901.
Auranen A, Grénman S, Mäkinen J et al.. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol 1996;144:548–553.
Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 2015;94:86–94.
Zanetta G, Rota S, Chiari S et al.. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001;19:2658–2664.
Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001;11:568–574.
Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204–1211.
- Search Google Scholar
- Export Citation
. Harris R Whittemore AS Itnyre J Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1204– 1211.
Trillsch F, Mahner S, Vettorazzi E et al.. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer 2015;112:660–666.
Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002;95:2380–2389.
Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002;16:513–527.
Longacre TA, McKenney JK, Tazelaar HD et al.. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005;29:707–723.
Sherman ME, Mink PJ, Curtis R et al.. Survival among women with borderline ovarian tumors and ovarian carcinoma. Cancer 2004;100:1045–1052.
Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002;86:34–37.
Guvenal T, Dursun P, Hasdemir PS et al.. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecol Oncol 2013;131:546–550.
du Bois A, Ewald-Riegler N, de Gregorio N et al.. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013;49:1905–1914.
Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006;103:841–847.
Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, Ronnett BM, eds. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer US; 2011:679–784.
Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002;16:499–512.
Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000;24:1465–1479.
Shushan A, Paltiel O, Gordon L, Schenker JG. Ovarian cancer of low malignant potential is not associated with positive familial history. Am J Obstet Gynecol 1996;175:507–508.
Gotlieb WH, Chetrit A, Menczer J et al.. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005;97:780–783.
Seidman JD, Soslow RA, Vang R et al.. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004;35:918–933.
Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331–1345.
Bell DA, Longacre TA, Prat J et al.. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 2004;35:934–948.
Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 2013;287:1187–1204.
Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151–160.
Gilks CB, Alkushi A, Yue JJ et al.. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol 2003;22:29–36.
May T, Virtanen C, Sharma M et al.. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 2010;117:9–17.
Sieben NL, Macropoulos P, Roemen GM et al.. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004;202:336–340.
Singer G, Oldt R III, Cohen Y et al.. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484–486.
Caduff RF, Svoboda-Newman SM, Ferguson AW et al.. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999;23:323–328.
Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995;27:367–371.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al.. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005;24:1053–1065.
Ronnett BM, Kajdacsy-Balla A, Gilks CB et al.. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 2004;35:949–960.
Shappell HW, Riopel MA, Smith Sehdev AE et al.. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002;26:1529–1541.
- Search Google Scholar
- Export Citation
. Shappell HW Riopel MA Smith Sehdev AE Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002; 26: 1529– 1541.
Vang R, Gown AM, Barry TS et al.. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006;25:83–89.
Shih IM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11:7273–7279.
Mok SC, Bell DA, Knapp RC et al.. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489–1492.
Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996;20:1319–1330.
Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 2003;27:725–736.
Slomovitz BM, Caputo TA, Gretz HF III et al.. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol 2002;26:592–600.
Bristow RE, Gossett DR, Shook DR et al.. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 2002;86:163–170.
Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 2002;26:1111–1128.
Chang SJ, Ryu HS, Chang KH et al.. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand 2008;87:476–481.
Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31:539–557.
Uzan C, Kane A, Rey A et al.. Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary. Oncologist 2011;16:189–196.
Winter WE III, Kucera PR, Rodgers W et al.. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 2002;100:671–676.
Boran N, Cil AP, Tulunay G et al.. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005;97:845–851.
Ren J, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol 2008;110:162–167.
Uzan C, Muller E, Kane A et al.. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol 2014;25:166–171.
Morris RT, Gershenson DM, Silva EG et al.. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 2000;95:541–547.
Gotlieb WH, Flikker S & Davidson B et al. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998;82:141–146.
Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992;47:150–158.
Gershenson DM, Silva EG, Levy L et al.. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096–1103.
Lin PS, Gershenson DM, Bevers MW et al.. The current status of surgical staging of ovarian serous borderline tumors. Cancer 1999;85:905–911.
Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991;42:124–130.
Camatte S, Morice P, Atallah D et al.. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002;195:332–338.
Kanat-Pektas M, Ozat M, Gungor T et al.. Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors? Arch Gynecol Obstet 2011;283:879–884.
Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120–127.
Desfeux P, Camatte S, Chatellier G et al.. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005;98:390–395.
Bostwick DG, Tazelaar HD, Ballon SC et al.. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58:2052–2065.
Shih KK, Garg K, Soslow RA et al.. Accuracy of frozen section diagnosis of ovarian borderline tumor. Gynecol Oncol 2011;123:517–521.
Crispens MA, Bodurka D, Deavers M et al.. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3–10.
Sutton GP, Bundy BN, Omura GA et al.. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991;41:230–233.
Tropé C, Kaern J, Vergote IB et al.. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993;51:236–243.
Shih KK, Zhou QC, Aghajanian C et al.. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol 2010;119:270–273.
Gershenson DM, Bodurka DC, Lu KH et al.. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 2015;33:2675–2682.
Fader AN, Java J, Ueda S et al.. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 2013;122(2 Pt 1):225–232.
Cowan RA, O'Cearbhaill RE, Gardner GJ et al.. Is it time to centralize ovarian cancer care in the United States? Ann Surg Oncol 2016;23:989–993.
Schmeler KM, Sun CC, Bodurka DC et al.. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008;108:510–514.
Gershenson DM, Sun CC, Lu KH et al.. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108:361–368.
Gershenson DM, Sun CC, Bodurka D et al.. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009;114:48–52.
Gershenson DM, Sun CC, Iyer RB et al.. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012;125:661–666.
Farley J, Brady WE, Vathipadiekal V et al.. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14:134–140.
Harter P, Gershenson D, Lhomme C et al.. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014;24(9 Suppl 3):S5–8.
Gourley C, Farley J, Provencher DM et al.. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer 2014;24(9 Suppl 3):S9–13.